Results 161 to 170 of about 1,395,710 (388)

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma

open access: yesBiomarker Research
Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL).
Vivian Jiang   +9 more
doaj   +1 more source

Genetic Engineering Methods in Primary T Cells

open access: yesAdvanced Therapeutics, EarlyView.
Primary T cells can be engineered to confer them with novel therapeutic functions, allowing them to treat a variety of conditions. Genetic engineering can be either stable or transient, aiming to either express or inhibit a target gene. This review discusses the various genetic engineering tools available as well as their characteristics and ...
Anthony Youssef, Hui‐Shan Li
wiley   +1 more source

Strategies for increasing accrual in cancer clinical trials: What is the evidence?

open access: yesCancer Medicine
Introduction Despite the importance of clinical trial participation among cancer patients, few participate—and even fewer patients from ethnic and racial minoritized groups.
Margo Michaels   +9 more
doaj   +1 more source

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

open access: yesNew England Journal of Medicine, 2017
S. Neelapu   +39 more
semanticscholar   +1 more source

Tryptophan Metabolite Indole‐3‐Aldehyde Induces AhR and c‐MYC Degradation to Promote Tumor Immunogenicity

open access: yesAdvanced Science, EarlyView.
Tryptophan metabolite Indole‐3‐aldehyde (I3A) downregulates cytosolic AhR and p‐ERK/c‐MYC proteins, together enhancing STAT3 phosphorylation and tumor immunogenicity. Overexpression of the Trp metabolic enzyme interleukin‐4‐induced gene‐1 (IL4I1) in tumor cells increases intracellular levels of I3A and enhances tumor immunogenicity.
Lei Cui   +19 more
wiley   +1 more source

Transitions of the Malignant Lymphoma Group [PDF]

open access: bronze, 1955
S. W. Berkheiser, James McClure
openalex   +1 more source

Tumor‐Associated Sympathetic Nerves Promote the Progression of Epstein‐Barr Virus‐Positive Diffuse Large B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
Sympathetic nerve innervation promotes the progression of Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma (EBV+ DLBCL) via β2‐adrenergic receptors. The discovery of enhanced nerve infiltration and β2AR expression reveals a novel mechanism and highlights the sympathetic–β2AR axis as a promising target for therapeutic intervention in EBV+ DLBCL.
Silan Huang   +10 more
wiley   +1 more source

Genomic landscape and distinct molecular subtypes of primary testicular lymphoma

open access: yesJournal of Translational Medicine
Primary testicular lymphoma (PTL) is a rare lymphoma predominantly occurring in the elderly male population. It is characterized by a limited response to treatment and a heightened tendency towards relapse.
Weilong Zhang   +11 more
doaj   +1 more source

Pulmonary malignant lymphomas and pseudolymphomas: Classification, therapy, and prognosis [PDF]

open access: bronze, 1963
Sidney L. Saltzstein
openalex   +1 more source

Radioimmunotherapy of Lymphoma

open access: yesArchive of Oncology, 2012
Radiolabeled monoclonal antibodies for the treatment of follicular low-grade non-Hodgkin’s lymphoma have been available for several years in the United States and more recently throughout Europe. Since their introduction to treatment of refractory or relapsed patients, they have been evaluated for efficacy earlier in the course of the disease including
openaire   +4 more sources

Home - About - Disclaimer - Privacy